A phase 2, open-label study of rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation.

Abstract

TPS4161 Background: Approximately 5% of unselected pancreatic cancer (PC) patients (pts), 10% of PC pts of Ashkenazi Jewish descent, and up to 19% of familial PC families, harbor a germline BRCA mu...